All In Biotech

Free tool

FAERS Monitor: Omniscan

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020123 or its brand name (Omniscan, Gadodiamide). Reports on generic versions are filed under their own applications.

Reports

3,361

Serious

3,114

93% of reports

Hospitalization

316

Death reported

374

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nephrogenic systemic fibrosis2,226
  • pain758
  • anxiety432
  • emotional distress398
  • injury397
  • mobility decreased355
  • arthralgia345
  • skin hypertrophy275
  • fibrosis273
  • general physical health deterioration270
  • skin induration266
  • oedema peripheral264
  • rash262
  • hypoaesthesia258
  • asthenia254

Reports by year received

View as table
YearReports
200417
200512
200653
2007246
2008295
2009258
2010360
2011351
2012137
2013115
2014714
201594
201682
2017101
201874
2019204
2020114
202131
202218
202324
202422
202517
202622

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,798 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
nephrogenic systemic fibrosisSignal2,22617449.316214.110,255,160
skin indurationSignal266921.0813.4212,328
skin hypertrophySignal275678.6602.1167,298
fibrosisSignal273609.1540.5150,528
injurySignal39735.532.413,259
mobility decreasedSignal35531.128.210,286
emotional distressSignal39820.618.87,436
general physical health deteriorationSignal27014.613.13,427
oedema peripheralSignal26413.612.13,075
hypoaesthesiaSignal25810.89.62,298
anxietySignal4329.58.73,322
painSignal7587.77.34,563
arthralgiaSignal3455.24.71,187
astheniaSignal2544.23.8634
rashSignal2623.83.3540

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.